 | By OncoBeta GmbH OncoBeta® GmbH has announced its first Sydney-based patients were treated with Rhenium-SCT® as part of the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of non-melanoma skin cancer [NMSC]).
|
 | By OncoBeta GmbH OncoBeta® GmbH, a medical device company specialized in innovative epidermal radioisotope therapies announced today that the company has received ethics approval from the National Health and Medical Research Council (NHMRC) in Australia to begin the...
|
 | By OncoBeta GmbH Today OncoBeta® GmbH, a medical device company specialising in innovative epidermal radioisotope therapies for non-melanoma skin cancers (NMSCs), has expanded its offering of non-invasive skin cancer therapy Rhenium-SCT® (Skin Cancer Therapy) in South...
|
 | By OncoBeta GmbH The multi-centre prospective study will evaluate the efficacy of the Rhenium-SCT® in non-melanoma skin cancer patients
|
 | By OncoBeta GmbH Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer is now available in Australia
|
 | By OncoBeta GmbH Province of Gauteng South Africa is first to offer an innovative single session keloid treatment without need of surgery
|
 | By OncoBeta GmbH Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer to be produced in Australia
|
 | By OncoBeta GmbH Grupo RPH is now the Official Rhenium-SCT® Sales Representative and Distributor in Brazil for the treatment of Non-Melanoma Skin Cancer.
|
